BioSpace News Archive

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024.

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes.

Windtree Therapeutics, Inc. today announced that it has engaged Ladenburg Thalmann & Co. Inc. (“Ladenburg”) to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value.

BellaSeno GmbH announced that additional, investigator-initiated clinical trials of its novel regenerative scaffolds for bone reconstruction and chest-wall defects will be conducted in Germany and Italy, respectively.

Zymeworks Inc. announced that management will participate in the following upcoming investor conferences.

Vizient, Inc. announced it is accepting applications for its 2024 Innovative Technology Exchange and encouraged suppliers of medical equipment and technology who want to showcase their products to health care decision makers from across the country to participate.

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024.

Trinity Biotech plc announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring biosensor device in China and India.

Trinity Biotech plc announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring assets of privately held Waveform Technologies, Inc. for $12.5 million in cash, 9 million American Depositary Shares of the Company and additional contingent consideration.